Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
| Status: | Completed |
|---|---|
| Conditions: | Chronic Pain, Psychiatric |
| Therapuetic Areas: | Musculoskeletal, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 21 - 45 |
| Updated: | 12/13/2017 |
| Start Date: | June 2008 |
| End Date: | May 2013 |
The following study is designed to determine the analgesic efficacy of smoked marijuana (0,
1.98, and 3.56% THC) and oral THC (0, 10, and 20 mg) in the Cold-Pressor Test (CPT), a
laboratory model of pain which has predictive validity for clinical use of analgesics. Oral
THC (dronabinol) is known to have a slower onset and longer duration of action compared with
smoked marijuana. Therefore, the analgesic effects of oral THC is expected to peak later and
last longer than effects produced by smoked marijuana.
1.98, and 3.56% THC) and oral THC (0, 10, and 20 mg) in the Cold-Pressor Test (CPT), a
laboratory model of pain which has predictive validity for clinical use of analgesics. Oral
THC (dronabinol) is known to have a slower onset and longer duration of action compared with
smoked marijuana. Therefore, the analgesic effects of oral THC is expected to peak later and
last longer than effects produced by smoked marijuana.
Laboratory animal studies have demonstrated the analgesic effects of drugs which act on the
cannabinoid system, however, these effects have et to be clearly elucidated in humans. To
better understand the potential clinical application of cannabinoids for pain management, the
following study is designed to determine the analgesic efficacy of smoked marijuana (3.56%
THC) and oral THC (20 mg) in the Cold-Pressor Test (CPT), a laboratory model of pain which
has predictive validity for clinical use of analgesics. Non-treatment seeking marijuana
smokers will be recruited for a five-session study during which the analgesic, subjective,
and physiologic effects of cannabinoids will be evaluated. Determining the efficacy of
cannabinoids in an experimental model of pain will provide important endpoints (i.e., dose,
route of administration, time course) or this effect to further investigate the potential
role for clinical use of smoked marijuana and/or oral THC as analgesics.
cannabinoid system, however, these effects have et to be clearly elucidated in humans. To
better understand the potential clinical application of cannabinoids for pain management, the
following study is designed to determine the analgesic efficacy of smoked marijuana (3.56%
THC) and oral THC (20 mg) in the Cold-Pressor Test (CPT), a laboratory model of pain which
has predictive validity for clinical use of analgesics. Non-treatment seeking marijuana
smokers will be recruited for a five-session study during which the analgesic, subjective,
and physiologic effects of cannabinoids will be evaluated. Determining the efficacy of
cannabinoids in an experimental model of pain will provide important endpoints (i.e., dose,
route of administration, time course) or this effect to further investigate the potential
role for clinical use of smoked marijuana and/or oral THC as analgesics.
Inclusion Criteria:
- Adults between the ages of 21-45
- Current marijuana use
- Able to perform study procedures
- Women practicing an effective form of birth control
Exclusion Criteria:
- Female subjects who are currently pregnant or breastfeeding
- Current,repeated illicit drug use other than marijuana
- Presence of significant medical illness
- History of heart disease
- Request for drug treatment
- Current parole or probation
- Recent history of significant violent behavior
We found this trial at
1
site
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials
